Register now!
  • Avicenna Alliance What is predictive medicine?

    Predictive or “in silico medicine” is the use of computer modelling and simulation in the diagnosis, treatment, prevention of a disease and development of products.

    read more

Avicenna Alliance news

In Silico – turning Big Data into Personalized Medicine, European Parliament

On 11 October 2016, MEPs Nicola Caputo (S&D, Italy) and Seán Kelly (EPP, Ireland) hosted the launch event of the Avicenna...

find out more ›

EC asks VPHi for input in Horizon 2020 Work Programme

The European Commission has requested that the Virtual Physiological Human Institute (VPHi), the Academic Research Membership of the Avicenna...

find out more ›

FDA to look towards Observer Status in Avicenna Alliance

The Avicenna Alliance has been in touch with the FDA on the issue of in silico medicine over the last number of months and has reached a new...

find out more ›

Avicenna Alliance review meeting with the European Commission

On 02 May 2016, Avicenna Alliance delegates met with representatives of DG Connect to discuss progress on in silico medicine in the 1st...

find out more ›

EC Appoints VPH to key stakeholder group

The European Commission has appointed the Virtual Physiological Human Institute (VPHi) to its eHealth Stakeholder Group. With VPHi representing 50% of the...

find out more ›

EMA Regulation Vote result – major gains for in silico

On 10 March 2016 the European Parliament through an overwhelming majority, voted in favour of requiring the EMA to take into account alternative...

find out more ›

Show all activites

Avicenna Alliance the Association for Predictive Medicine

The Association for Predictive Medicine, is an association of industry and research organisations who have a commercial or research interest in in silico medicine. The Association, established in 2015, has its origins in the Virtual Physiological Human Initiative, a European Commission funded project focused on research into in silico medicine. Tasked by the European Commission with developing a “Roadmap for in silico medicine”, the Association now seeks to put this roadmap into policy and ensure the development of a regulated in silico market. 

This Association bridges the gap between the scientific community, industry and policy makers by advocating for policy changes that take into account scientific and market developments.

read more

Avicenna Alliance: 
enhanced knowledge, improved decisions, better outcomes